Cagrilintide for Obesity

This trial aims to compare two versions of a treatment called cagrilintide, an injectable medication, to evaluate their effectiveness in aiding weight loss for individuals with excess body weight. Participants will receive weekly injections of either cagrilintide B or cagrilintide D for five weeks, with the specific treatment assigned randomly. This study suits adults with a body mass index (BMI) between 27.0 and 34.9, indicating overweight status due to extra body fat. The study spans approximately 14 weeks, during which researchers will monitor health changes. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that cagrilintide, the treatment under study, is generally well-tolerated by individuals who are overweight. One study found that cagrilintide significantly aided weight loss and was well-received by patients. However, some participants experienced side effects, primarily digestive issues like nausea. In another study, about 72.5% of those taking cagrilintide with another medication reported digestive issues, compared to 34.4% in the placebo group. Additionally, cagrilintide alone posed a higher risk of serious side effects compared to another weight-loss drug. This suggests that while the treatment may aid weight loss, it can cause side effects that some might find uncomfortable.¹²³⁴⁵

Researchers are excited about cagrilintide for obesity because it offers a novel approach to weight management. Unlike other treatments that mainly target appetite suppression through the gut-brain axis, cagrilintide is a long-acting amylin analog that enhances satiety and slows gastric emptying, potentially leading to more significant weight loss. This unique mechanism of action sets it apart from standard options like GLP-1 agonists or lifestyle modifications, providing a fresh avenue for tackling obesity. Plus, it's administered just once a week via a simple subcutaneous injection, which could make it more convenient for patients compared to daily medications.

Earlier research has shown that cagrilintide helps people with obesity lose weight. In one study, participants lost an average of 7 kg more than those who took a placebo over 26 weeks. Another study found that combining cagrilintide with semaglutide led to a 13.7% body weight loss, compared to just 3.4% with a placebo. This trial will evaluate two versions of cagrilintide: Cagrilintide B and Cagrilintide D. These findings suggest that cagrilintide effectively aids in weight loss and is generally well tolerated by patients.¹²³⁴⁶